Drug Profile
Pirepemat - Integrative Research Laboratories
Alternative Names: IRL-752Latest Information Update: 14 Dec 2023
Price :
$50
*
At a glance
- Originator Integrative Research Laboratories
- Class Antidementias; Antidepressants; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Ethers; Fluorobenzenes; Pyrrolidines; Small molecules
- Mechanism of Action Alpha adrenergic receptor antagonists; Serotonin 7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
- No development reported Behavioural disorders
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 12 Dec 2023 IRLAB Therapeutics has patent protection for the API of pirepemat and the process for its preparation in Europe, China, Japan and USA
- 12 Dec 2023 IRLAB Therapeutics plans a phase III trial for Parkinson's disease (PO)
- 17 Jul 2023 Data and Safety Monitoring Board (DSMB) recommends continuation of phase-IIb React PD trial of Pirepemat for Parkinson's Disease in France, Germany, Poland, the Netherlands, Spain, and Sweden